An automatic dose dispenser for microtablets - A new concept for individual dosage of drugs in tablet form

International Journal of Pharmaceutics

Volumn 261, Issue 1-2, 2003, Pages 137-146

  Bredenberg, Susanne ^a   Nyholm, Dag ^b   Aquilonius, Sten Magnus ^b   Nyström, Christer ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Drug dispensing device; Individual dosage; Levodopa; Microtablets; Parkinson's disease

Indexed keywords

CARBIDOPA; LEVODOPA; LEVOTHYROXINE; MAGNESIUM STEARATE; MICROCRYSTALLINE CELLULOSE; MORPHINE; WARFARIN;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEVICE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENTIATION; DYSKINESIA; ELECTRONICS; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STANDARDIZATION; TABLET;

EID: 0043095485     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00294-1     Document Type: Article

References (36)

1. Agid Y. Parkinson's disease: pathophysiology. Lancet. 337:1991;1321-1327.
2. Alderborn G., Duberg M., Nyström C. Studies on direct compression of tablets X. Measurement of tablet surface area by permeametry. Powder Technol. 41:1985;49-56.
3. Aquilonius S.-M., Sandell A., Sundell S., Nyström C. A handy dose-automat for adjustable delivery of oral levodopa/carbidopa. Mov. Disord. 13:1998;79.
4. Bergqvist, D., Johnsson, H., 1999. Venös tromboembolism och antikoagulantia. In: Apoteket, A.B. (Ed.), Läkemedelsboken 1999/2000. Graphium Print & Distribution AB. Bromma, Sweden, pp. 194-214.
5. Bredberg E., Nilsson D., Johansson K., Aquilonius S.-M., Johnels B., Nyström C., Paalzow L. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur. J. Clin. Pharmacol. 45:1993;117-122.
6. B.S. 2955, 1958. Glossary of Terms Relating to Powders, No. 505. British Standards Institute, Park Street, London.
7. Contin M., Riva R., Martinelli P., Cortelli P., Albani F., Baruzzi A. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. Clin. Neuropharmacol. 22:1999;351-355.
8. Durif F. Treating and preventing levodopa-induced dyskinesias. Current and future strategies. Drugs Aging. 14:1999;337-345.
9. European Pharmacopeia, 2002. Convention on the Elaboration of a European Pharmacopeia, 4th ed. Council of Europe, Strasbourg Cedex, France, pp. 199-200.
10. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 286:1999;487-491.
11. Evans W.E., Relling M.V., Rodman J.H., Crom W.R., Boyett J.M., Pui C.-H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. 338:1998;499-505.
12. Fahn, S., Elton, R., Members of the UPDRS Development Committee, 1987. In: Fahn, S., Marsden, C.D., Calne, D.B., Goldstein, M. (Eds.), Recent Developments in Parkinson's Disease, vol. 2. Macmillan Health Care Information, Florham Park, NJ, pp. 153-163.
13. Fell J.T., Newton J.M. Determination of tablet strength by diametral-compression test. J. Pharm. Sci. 59:1970;688-691.
14. Fredholm B.B., Sjöqvist F. Pharmacology at the start of a new millennium. Larger assortment and individual drug dosing are coming. Läkartidningen (in Swedish). 98:2001;534-539.
15. Grahnén A., Eckernäs S.-Å., Collin C., Ling-Andersson A., Tiger G., Nilsson M. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products. Eur. Neurol. 32:1992;343-348.
16. Granérus, A.-K., 1999. Parkinsons sjukdom. In: Apoteket, A.B. (Ed.), Läkemedelsboken 1999/2000. Graphium Print & Distribution AB. Bromma, Sweden, pp. 743-753.
17. Hallengren, B., 1999. Tyreoideasjukdomar. In: Apoteket, A.B. (Ed.), Läkemedelsboken 1999/2000. Graphium Print & Distribution AB. Bromma, Sweden, pp. 510-521.
18. Hasselström, J., Olsson, G.L., 1999. Smärta. In: Apoteket, A.B. (Ed.), Läkemedelsboken 1999/2000. Graphium Print & Distribution AB. Bromma, Sweden, pp. 677-699.
19. Janko K.A., Goetz C., Stebbins G. A survival study of Parkinson's disease patients switched to liquid carbidopa/L-dopa. Mov. Disord. 17:2002;S92-S93.
20. Jerwanska E., Alderborn G., Newton J.M., Nyström C. The effect of water content on the porosity and liquid saturation of extruded cylinders. Int. J. Pharm. 121:1995;65-71.
21. Kaye B.H. Permeability techniques for characterizing fine powders. Powder Technol. 1:1967;11-22.
22. Kurth M.C. Using liquid levodopa in the treatment of Parkinson's disease. a practical guide. Drugs Aging. 10:1997;332-340.
23. Kurth M.C., Tetrud J.W., Irwin B.A., Lyness W.H., Langston J.W. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology. 43:1993;1036-1039.
24. Lees A.J. Drugs for Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 73:2002;607-610.
25. Marsden C.D., Parkes J.D. "On-Off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 7:1976;292-296.
26. Marsden C.D., Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1:1977;345-349.
27. Merims D., Djaldetti R., Melamed E. Waiting for on: a major problem in patients with Parkinson's disease and on-off motor fluctuations. Mov. Disord. 17:2002;S81.
28. Nilsson D., Nyholm D., Aquilonius S.-M. Duodenal levodopa infusion in Parkinson's disease: long-term experience. Acta Neurol. Scand. 104:2001;343-348.
29. Nyholm D., Lennernäs H., Gomes-Trolin C., Aquilonius S.-M. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin. Neuropharmacol. 25:2002;89-96.
30. Pappert E.J., Goetz C.G., Niederman F., Ling Z.D., Stebbins G.T., Carvey P.M. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology. 47:1996;1493-1495.
31. Pietz K., Hagell P., Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long-term follow-up. J. Neurol. Neurosurg. Psychiatr. 65:1998;709-716.
32. Rinne U.K. Problems associated with long-term levodopa treatment of Parkinson's disease. Acta Neurol. Scand. S95:1983;19-26.
33. Sjöqvist F. The past, present and future of clinical pharmacology. Eur. J. Clin. Pharmacol. 55:1999;553-557.
34. Teng J., Song C.K., Williams R.L., Polli J.E. Lack of medication dose uniformity in commonly split tablets. J. Am. Pharm. Assoc. 42:2002;195-199.
35. Verhagen Metman L., Hoff J., Mouradian M.M., Chase T.N. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov. Disord. 9:1994;463-465.
36. Wooten G.F. Progress in understanding the pathophysiology of treatment-related fluctuations in Parkisons disease. Ann. Neurol. 24:1988;363-365.